Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy

Alessandro Morlacco, Fabrizio Dal Moro, Laureano J. Rangel, Rachel E. Carlson, Phillip Schulte, Karnes R. Jeffrey

Research output: Contribution to journalArticle

Abstract

Purpose: The associations between metabolic syndrome (MetS) and prostate cancer (CaP) outcomes following radical prostatectomy (RP) are not clear. This study aims to understand the role of MetS in influencing oncological outcomes at RP. Materials and methods: Patients who underwent RP for CaP at our institution from 2000 to 2010 were identified; MetS prior to RP was ascertained with a modified version of the IDF-AHA/NHLBI using ICD-9 codes. Histopathological outcomes included surgical margins, pathological stage, and Gleason score (GS) upgrading. Long-term outcomes included biochemical recurrence (BCR), local recurrence, systemic progression, and CaP-specific mortality. Multivariable adjusted logistic regression and Cox proportional hazards regression assessed the association between MetS status and histopathological and long-term outcomes, respectively. Results: Of 8,504 RP patients, 1,054 (12.4%) had MetS at the time of RP. MetS patients were older, had higher biopsy GS, but lower pre-op prostatic specific antigen (PSA), higher pathological GS, and larger prostate volume. Adjusted logistic regression suggested an association between MetS and positive margins (odds ratio [OR] = 1.22, P = 0.025) and GS upgrading (OR = 1.28, P = 0.002). There was evidence of an increased risk of local recurrence (hazard ratio [HR] = 1.33, P = 0.037) and CaP-specific mortality (HR = 1.58, P < 0.001) for MetS patients. There was no evidence to suggest an association with BCR or systemic progression. Conclusion: Men with MetS are at higher risk of GS upgrade and positive surgical margins at surgery, local recurrence, and CaP-specific mortality. Pathological stage, BCR, and systemic progression were not associated with MetS. Our data may be useful in patients’ counseling, especially when active surveillance is an option.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Prostatectomy
Neoplasm Grading
Recurrence
International Classification of Diseases
Mortality
Logistic Models
Odds Ratio
National Heart, Lung, and Blood Institute (U.S.)
Counseling
Prostate
Prostatic Neoplasms
Biopsy
Antigens

Keywords

  • Metabolic syndrome
  • Oncological outcomes
  • Prostate cancer
  • Radical prostatectomy
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy. / Morlacco, Alessandro; Moro, Fabrizio Dal; Rangel, Laureano J.; Carlson, Rachel E.; Schulte, Phillip; Jeffrey, Karnes R.

In: Urologic Oncology: Seminars and Original Investigations, 01.01.2018.

Research output: Contribution to journalArticle

Morlacco, Alessandro ; Moro, Fabrizio Dal ; Rangel, Laureano J. ; Carlson, Rachel E. ; Schulte, Phillip ; Jeffrey, Karnes R. / Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy. In: Urologic Oncology: Seminars and Original Investigations. 2018.
@article{1bad2db54b714f95ac67f92b095ae349,
title = "Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy",
abstract = "Purpose: The associations between metabolic syndrome (MetS) and prostate cancer (CaP) outcomes following radical prostatectomy (RP) are not clear. This study aims to understand the role of MetS in influencing oncological outcomes at RP. Materials and methods: Patients who underwent RP for CaP at our institution from 2000 to 2010 were identified; MetS prior to RP was ascertained with a modified version of the IDF-AHA/NHLBI using ICD-9 codes. Histopathological outcomes included surgical margins, pathological stage, and Gleason score (GS) upgrading. Long-term outcomes included biochemical recurrence (BCR), local recurrence, systemic progression, and CaP-specific mortality. Multivariable adjusted logistic regression and Cox proportional hazards regression assessed the association between MetS status and histopathological and long-term outcomes, respectively. Results: Of 8,504 RP patients, 1,054 (12.4{\%}) had MetS at the time of RP. MetS patients were older, had higher biopsy GS, but lower pre-op prostatic specific antigen (PSA), higher pathological GS, and larger prostate volume. Adjusted logistic regression suggested an association between MetS and positive margins (odds ratio [OR] = 1.22, P = 0.025) and GS upgrading (OR = 1.28, P = 0.002). There was evidence of an increased risk of local recurrence (hazard ratio [HR] = 1.33, P = 0.037) and CaP-specific mortality (HR = 1.58, P < 0.001) for MetS patients. There was no evidence to suggest an association with BCR or systemic progression. Conclusion: Men with MetS are at higher risk of GS upgrade and positive surgical margins at surgery, local recurrence, and CaP-specific mortality. Pathological stage, BCR, and systemic progression were not associated with MetS. Our data may be useful in patients’ counseling, especially when active surveillance is an option.",
keywords = "Metabolic syndrome, Oncological outcomes, Prostate cancer, Radical prostatectomy, Recurrence",
author = "Alessandro Morlacco and Moro, {Fabrizio Dal} and Rangel, {Laureano J.} and Carlson, {Rachel E.} and Phillip Schulte and Jeffrey, {Karnes R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2018.10.003",
language = "English (US)",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy

AU - Morlacco, Alessandro

AU - Moro, Fabrizio Dal

AU - Rangel, Laureano J.

AU - Carlson, Rachel E.

AU - Schulte, Phillip

AU - Jeffrey, Karnes R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The associations between metabolic syndrome (MetS) and prostate cancer (CaP) outcomes following radical prostatectomy (RP) are not clear. This study aims to understand the role of MetS in influencing oncological outcomes at RP. Materials and methods: Patients who underwent RP for CaP at our institution from 2000 to 2010 were identified; MetS prior to RP was ascertained with a modified version of the IDF-AHA/NHLBI using ICD-9 codes. Histopathological outcomes included surgical margins, pathological stage, and Gleason score (GS) upgrading. Long-term outcomes included biochemical recurrence (BCR), local recurrence, systemic progression, and CaP-specific mortality. Multivariable adjusted logistic regression and Cox proportional hazards regression assessed the association between MetS status and histopathological and long-term outcomes, respectively. Results: Of 8,504 RP patients, 1,054 (12.4%) had MetS at the time of RP. MetS patients were older, had higher biopsy GS, but lower pre-op prostatic specific antigen (PSA), higher pathological GS, and larger prostate volume. Adjusted logistic regression suggested an association between MetS and positive margins (odds ratio [OR] = 1.22, P = 0.025) and GS upgrading (OR = 1.28, P = 0.002). There was evidence of an increased risk of local recurrence (hazard ratio [HR] = 1.33, P = 0.037) and CaP-specific mortality (HR = 1.58, P < 0.001) for MetS patients. There was no evidence to suggest an association with BCR or systemic progression. Conclusion: Men with MetS are at higher risk of GS upgrade and positive surgical margins at surgery, local recurrence, and CaP-specific mortality. Pathological stage, BCR, and systemic progression were not associated with MetS. Our data may be useful in patients’ counseling, especially when active surveillance is an option.

AB - Purpose: The associations between metabolic syndrome (MetS) and prostate cancer (CaP) outcomes following radical prostatectomy (RP) are not clear. This study aims to understand the role of MetS in influencing oncological outcomes at RP. Materials and methods: Patients who underwent RP for CaP at our institution from 2000 to 2010 were identified; MetS prior to RP was ascertained with a modified version of the IDF-AHA/NHLBI using ICD-9 codes. Histopathological outcomes included surgical margins, pathological stage, and Gleason score (GS) upgrading. Long-term outcomes included biochemical recurrence (BCR), local recurrence, systemic progression, and CaP-specific mortality. Multivariable adjusted logistic regression and Cox proportional hazards regression assessed the association between MetS status and histopathological and long-term outcomes, respectively. Results: Of 8,504 RP patients, 1,054 (12.4%) had MetS at the time of RP. MetS patients were older, had higher biopsy GS, but lower pre-op prostatic specific antigen (PSA), higher pathological GS, and larger prostate volume. Adjusted logistic regression suggested an association between MetS and positive margins (odds ratio [OR] = 1.22, P = 0.025) and GS upgrading (OR = 1.28, P = 0.002). There was evidence of an increased risk of local recurrence (hazard ratio [HR] = 1.33, P = 0.037) and CaP-specific mortality (HR = 1.58, P < 0.001) for MetS patients. There was no evidence to suggest an association with BCR or systemic progression. Conclusion: Men with MetS are at higher risk of GS upgrade and positive surgical margins at surgery, local recurrence, and CaP-specific mortality. Pathological stage, BCR, and systemic progression were not associated with MetS. Our data may be useful in patients’ counseling, especially when active surveillance is an option.

KW - Metabolic syndrome

KW - Oncological outcomes

KW - Prostate cancer

KW - Radical prostatectomy

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85056412954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056412954&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2018.10.003

DO - 10.1016/j.urolonc.2018.10.003

M3 - Article

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

ER -